No Data
No Data
RBC Capital Maintains Gilead Sciences(GILD.US) With Hold Rating, Maintains Target Price $74
RBC Capital analyst Brian Abrahams maintains $Gilead Sciences(GILD.US)$ with a hold rating, and maintains the target price at $74.According to TipRanks data, the analyst has a success rate of 49.4% an
EU to Require Additional Cancer Risk Labeling on CAR T Therapies
Gilead Stock Gains. It's Trying to Get Into the Obesity Drug Game.
A success would be a gamechanger for the biotech company known for its HIV treatments.
What 8 Analyst Ratings Have To Say About Gilead Sciences
In the last three months, 8 analysts have published ratings on Gilead Sciences (NASDAQ:GILD), offering a diverse range of perspectives from bullish to bearish.The table below provides a snapshot of th
Gilead Spikes as Jefferies Highlights Weight Loss Prospects
Express News | RBC Capital Reiterates Sector Perform on Gilead Sciences, Maintains $74 Price Target
No Data